The Effect of Metformin on Diastolic Function in Patients Presenting with ST-Elevation Myocardial Infarction.

ABSTRACT:

Introduction

Diastolic dysfunction is an important predictor of poor outcome after myocardial infarction. Metformin treatment improved diastolic function in animal models and patients with diabetes. Whether metformin improves diastolic function in patients presenting with ST-segment elevation myocardial infarction (STEMI) is unknown.

Methods

The GIPS-III trial randomized STEMI patients, without known diabetes, to metformin or placebo initiated directly after PCI. The previously reported primary endpoint was left ventricular ejection fraction at 4 months, which was unaffected by metformin treatment. This is a predefined substudy to determine an effect of metformin on diastolic function. For this substudy trans-thoracic echocardiography was performed during hospitalization and

SUBMITTER: Al Ali L 

PROVIDER: S-EPMC5158040 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature